Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BeiGene Ltd ( (HK:6160) ) has issued an announcement.
BeOne Medicines Ltd., a corporation incorporated under the laws of Switzerland, announced the grant of Restricted Share Units (RSUs) under its 2016 Share Option and Incentive Plan. On June 30, 2025, the company’s compensation committee granted a total of 43,839 RSUs, representing 569,907 underlying shares, to 216 grantees. This grant accounts for approximately 0.04% of the total issued shares. The RSUs will vest over four years, with specific conditions for accelerated vesting in certain cases. This move is part of the company’s ongoing efforts to incentivize and retain its employees.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 7,293,214
Technical Sentiment Signal: Buy
Current Market Cap: HK$241.1B
Learn more about 6160 stock on TipRanks’ Stock Analysis page.